[1]闫朝武,方纬,汪蕾.儿童肥厚型心肌病磁共振延迟强化特征分析[J].国际放射医学核医学杂志,2018,(3):233-236,256.[doi:10.3760/cma.j.issn.1673-4114.2018.03.007]
　Yan Chaowu,Fang Wei,Wang Lei.Characteristics of late gadolinium enhancement in children with hypertrophic cardiomyopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):233-236,256.[doi:10.3760/cma.j.issn.1673-4114.2018.03.007]
点击复制

儿童肥厚型心肌病磁共振延迟强化特征分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第3期
页码:
233-236,256
栏目:
临床研究
出版日期:
2018-05-25

文章信息/Info

Title:
Characteristics of late gadolinium enhancement in children with hypertrophic cardiomyopathy
作者:
闫朝武1;  方纬2;  汪蕾2
1. 100037 北京, 国家心血管病中心 中国医学科学院阜外医院结构性心脏病中心;
2. 100037 北京, 国家心血管病中心 中国医学科学院阜外医院核医学科
Author(s):
Yan Chaowu1;  Fang Wei2;  Wang Lei2
1. National Center for Cardiovascular Diseases, Department of Structural Heart Disease, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China;
2. National Center of Cardiovasculan Diseases, Department of Nuclear Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
关键词:
心肌病; 肥厚性; 儿童; 磁共振成像; 延迟强化
Keywords:
Cardiomyopathy; Hypertrophic; Children; Magnetic resonance imaging; Late gadolinium enhancement
DOI:
10.3760/cma.j.issn.1673-4114.2018.03.007
摘要:
目的 分析肥厚型心肌病（HCM）患儿心脏受累心肌MRI对比剂延迟强化发生率及其与预后的相关性。方法 收集2006年1月至2012年1月我院收治的HCM患儿71例，所有患儿均接受心脏MRI检查，并行对比剂增强心肌显像。根据左心室心肌是否存在延迟强化，将患儿分为延迟强化组和非延迟强化组，并进一步分析受累心肌对比剂延迟强化的范围及程度等。应用Kaplan-Meier生存曲线分析两组患儿的预后差别，两组临床数据间的统计分析采用t检验。结果 71例HCM患儿中，9例（12.7%）患儿左心室为对称性肥厚，其中2例患儿进展至终末期。52例（73%）患儿出现心肌延迟强化，其延迟强化组患儿左心室质量高于非延迟强化组患儿[（112.7±57.9） g/m2 vs.（70.3±37.4） g/m2]，两组间差异有统计学意义（t=2.71，P=0.025）；但两组左室室壁厚度[（19.4±6.3） mm/m2 vs.（18.1±7.9） mm/m2]比较，差异无统计学意义（t=0.69，P=0.513）。HCM患儿随访（2.4±1.6）年显示，心肌延迟强化与不良心血管事件的发生密切相关（χ2=4.77，P=0.029）。结论 HCM患儿中，其心肌延迟强化发生率与成人患者接近，并且心肌延迟强化具有判断患儿预后的临床价值。
Abstract:
Objective To analyze the prevalence of late gadolinium enhancement (LGE) in children with idiopathic hypertrophic cardiomyopathy(HCM). Methods Cardiac magnetic resonance imaging(CMR) was performed consecutively in 71 children with idiopathic HCM(12.8 ±4.1 years old; 46 males, 25 females) from January 2006 to January 2012. Left ventricular (LV) parameters indexed by the body surface area were calculated, and LGE was carried out. Kaplan-Meier survival curves were generated, and differences in the two groups were compared via a log-rank test. Results Of the total number of children with HCM, 9 patients (12.7%) had concentric LV hypertrophy, and 2 of these 9 patients progressed into an end-stage phase. The prevalence of LGE was 73%. The LV mass index of the children with HCM subjected to LGE was greater than that of the other group[(112.7±57.9) g/m2 vs. (70.3±37.4) g/m2, t=2.71, P=0.025], but their maximal LV wall thickness index was not significantly different[(19.4±6.3) vs. (18.1±7.9) mm/m2, t=0.69, P=0.513]. Follow-up (2.4±1.6 years) revealed that LGE was associated with the adverse events in children with HCM (log-rank, χ2=4.77, P=0.029). Conclusions The prevalence of LGE in childhood HCM was similar to that in adult HCM. Children with HCM subjected to LGE likely suffered from adverse events.

参考文献/References:

[1] Maron MS, Maron BJ. Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy[J]. Circulation, 2015, 132(4):292-298. DOI:10.1161/CIRCULATIONAHA.114.014283.
[2] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 124(24):2761-2796. DOI:10.1161/CIR.0b013e318223e230.
[3] Briasoulis A, Mallikethi-Reddy S, Palla M, et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy:a meta-analysis[J]. Heart, 2015, 101(17):1406-1411. DOI:10.1136/heartjnl-2015-307682.
[4] Choi HM, Kim KH, Lee JM, et al. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy[J]Heart, 2015, 101(11):870-876. DOI:10.1136/heartjnl-2014-306555.
[5] Mclellan AJ, Ellims AH, Prabhu S, et al. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Mmaging Associates with Ventricular Tachycardia in Patients with Hypertrophic Cardiomyopathy[J]. J Cardiovasc Electrophysiol, 2016, 27(5):571-580. DOI:10.1111/jce.12948.
[6] Ellims AH, Iles LM, Ling LH, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype[J]. Eur Heart J Cardiovasc Imaging, 2014, 15(10):1108-1116. DOI:10.1093/ehjci/jeu077.
[7] Chaowu Y, Li L, Shihua Z. Histopathological features of delayed enhancement cardiovascular magnetic resonance in isolated left ventricular noncompaction[J]. J Am Coll Cardiol, 2011, 58(3):311-312. DOI:10.1016/j.jacc.2011.02.053.
[8] Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2010, 56(11):875-887. DOI:10.1016/j.jacc.2010.05.007.
[9] Ismail TF, Jabbour A, Gulati A, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy[J]. Heart, 2014,100(23):1851-1858. DOI:10.1136/heartjnl-2013-305471.
[10] Hurtado-de-Mendoza D, Corona-Villalobos CP, Pozios I, et al. Diffuse interstitial fibrosis assessed by cardiac magnetic resonance is associated with dispersion of ventricular repolarization in patients with hypertrophic cardiomyopathy[J]. J Arrhythm, 2017, 33(3):201-207. DOI:10.1016/j.joa.2016.10.005.
[11] Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2012, 60(10):922-929. DOI:10.1016/j.jacc.2012.03.076.
[12] Sato Y, Matsumoto N, Yoda S, et al. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm: report of 2 cases[J/OL]. Int J Cardiol, 2008, 129(3):e88-90[2018-03-18]. https://www.sciencedirect.com/science/article/pii/S0167527307014799?via%3Dihub. DOI:10.1016/j.ijcard.2007.06.134.
[13] 王妍, 何继强, 高阅春, 等. 711例肥厚型心肌病患者临床特征分析[J]. 中国循环杂志, 2011, 26(6): 434-437. DOI:10.3969/j.issn.1000-3614.2011.06.010. Wang Y, He JQ, Gao YC, et al. Clinical characteristic analysis of hypertrophic cardiomyopathy in 711 patients[J]. Chin Circul J, 2011, 26(6):434-437.
[14] 李华, 闫朝武, 徐仲英, 等. 肥厚型心肌病合并左心室心尖部室壁瘤患者的临床特征[J].中国循环杂志, 2016, 31(7):679-682. DOI:10.3969/j.issn.1000-3614.2016.07.014. Li H, Yan CW, Xu ZY, et al. Clinical features in patients with hypertrophic cardiomyopathy combining left ventricular apical aneurysm[J]. Chin Circul J, 2016, 31(7):679-682.

相似文献/References:

[1]田月琴.核素显像鉴别缺血性和扩张性心肌病的综合评价[J].国际放射医学核医学杂志,2000,24(1):7.
　TIAN Yue-qin.Comprehensive evaluation of radionuclide techniques in differentiating dilated cardiomyopathy and ischemic cardiomyopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):7.

备注/Memo

备注/Memo:
收稿日期:2018-03-19。
基金项目:国家自然科学基金（81670283）；北京市自然科学基金（7162160）；首都临床特色应用研究（Z171100001017194）
通讯作者:闫朝武,Email:chaowuyan@163.com
更新日期/Last Update: 2018-05-25